Anti‐ CD38 therapy in immune thrombocytopenia ( ITP )
Abstract
Anti‐CD38 monoclonal antibodies have demonstrated rapid responses in immune thrombocytopenia, with response rates across several agents ranging from moderate to high. However, the durability of these responses after treatment discontinuation appears to vary. The therapeutic effects of anti‐CD38 antibodies likely extend beyond depletion of CD38 + plasma cells and may involve broader modulation of the immune system.
Fields of Study & Subjects
Platelet Disorders and Treatments
Heparin-Induced Thrombocytopenia and Thrombosis
Multiple Myeloma Research and Treatments
Publication details
- Journal / source
- British Journal of Haematology
- Publisher
- Wiley
- Volume
- 209
- Issue
- 1
- Pages
- 28–30
- Publication date
- 23 April 2026
- Language
- EN